Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2016 1
2018 1
2019 1
2020 4
2021 4
2022 5
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Short NJ, et al. Among authors: chien ks. J Clin Oncol. 2024 Jan 26:JCO2301911. doi: 10.1200/JCO.23.01911. Online ahead of print. J Clin Oncol. 2024. PMID: 38277619
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Senapati J, et al. Among authors: chien ks. Blood. 2023 Nov 9;142(19):1647-1657. doi: 10.1182/blood.2023020649. Blood. 2023. PMID: 37441846
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Bataller A, et al. Among authors: chien ks. Am J Hematol. 2023 Nov;98(11):1780-1790. doi: 10.1002/ajh.27070. Epub 2023 Sep 4. Am J Hematol. 2023. PMID: 37665752
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. Bataller A, et al. Among authors: chien ks. Leuk Res. 2023 Apr;127:107044. doi: 10.1016/j.leukres.2023.107044. Epub 2023 Feb 15. Leuk Res. 2023. PMID: 36801700 No abstract available.
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. Desikan SP, et al. Among authors: chien ks. Acta Haematol. 2022;145(5):529-536. doi: 10.1159/000525566. Epub 2022 Jun 17. Acta Haematol. 2022. PMID: 35717939 Free article. Clinical Trial.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bazinet A, et al. Among authors: chien ks. Cancer. 2023 Feb 15;129(4):560-568. doi: 10.1002/cncr.34564. Epub 2022 Dec 2. Cancer. 2023. PMID: 36458426 Free article.
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Bazinet A, et al. Among authors: chien ks. Clin Cancer Res. 2024 Apr 1;30(7):1319-1326. doi: 10.1158/1078-0432.CCR-23-2860. Clin Cancer Res. 2024. PMID: 38300723
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Urrutia S, et al. Among authors: chien ks. Am J Hematol. 2023 Oct;98(10):E281-E284. doi: 10.1002/ajh.27043. Epub 2023 Jul 29. Am J Hematol. 2023. PMID: 37515433
28 results